Paclitaxel is effective in relapsed head and neck squamous cell carcinoma: a retrospective study of 66 patients at a single institution
- 1 June 2010
- journal article
- Published by Ovid Technologies (Wolters Kluwer Health) in Anti-Cancer Drugs
- Vol. 21 (5), 553-558
- https://doi.org/10.1097/cad.0b013e3283388e60
Abstract
The standard first-line treatment of recurrent/metastatic head and neck squamous cell carcinoma is cisplatin-based chemotherapy, but taxanes can also be beneficial after progression or in patients not eligible for cisplatin. The objective of this retrospective study was to evaluate paclitaxel in this population. We reviewed 66 patients who were treated with paclitaxel at a single institution (Lyon, France) between January 2003 and November 2008. Paclitaxel was administered as first, second or more line of treatment; alone or in combination with carboplatin or cetuximab; every 3 weeks (175 mg/m2) or weekly (80 mg/m2). Forty-six (70%) patients received paclitaxel as first-line therapy after relapse and 26 (39%) patients as monotherapy. The objective response rate was 30% [95% confidence interval (CI): 20–43%]; 37% (95% CI: 23–52%) in the first line after relapse, and 20% (95% CI: 4–48%) in the second line. Rates were 19% (95% CI: 7–39%) after monotherapy and 36% (95% CI: 20–55%) after combination with carboplatin. Two of the six patients receiving cetuximab had a partial response. The overall survival of all patients was 7.2 months (95% CI: 5.2–8.8). Paclitaxel can be used in symptomatic patients. Although no improvement of overall survival can be expected, paclitaxel treatment is safe and achieves interesting response rates.Keywords
This publication has 30 references indexed in Scilit:
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal Of Cancer, 2009
- Weekly paclitaxel for platin-resistant stage IV head and neck cancer patientsActa Oto-Laryngologica, 2009
- Platinum-Based Chemotherapy plus Cetuximab in Head and Neck CancerNew England Journal of Medicine, 2008
- Weekly Paclitaxel in the Adjuvant Treatment of Breast CancerNew England Journal of Medicine, 2008
- Cisplatin, Fluorouracil, and Docetaxel in Unresectable Head and Neck CancerNew England Journal of Medicine, 2007
- Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck CancerNew England Journal of Medicine, 2007
- Cancer Statistics, 2006CA: A Cancer Journal for Clinicians, 2006
- Randomized Phase III Evaluation of Cisplatin Plus Fluorouracil Versus Cisplatin Plus Paclitaxel in Advanced Head and Neck Cancer (E1395): An Intergroup Trial of the Eastern Cooperative Oncology GroupJournal of Clinical Oncology, 2005
- Randomized phase III trial of edatrexate versus methotrexate in patients with metastatic and/or recurrent squamous cell carcinoma of the head and neck: a European Organization for Research and Treatment of Cancer Head and Neck Cancer Cooperative Group study.Journal of Clinical Oncology, 1995
- Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study.Journal of Clinical Oncology, 1992